Rant

Budget cuts hitting R&D hard?

0x532e…653d

·3d ago·2 comments

Been working in R&D here for a while and the vibe has shifted. We're seeing major pushback on nearly every new project proposal, even ones that seem promising. Smaller initiatives are getting scrapped left and right, and there's a huge emphasis on 'efficiency' and 'streamlining'. Feels like the money tap is slowly being turned off. Heard rumors about the next budget cycle being significantly tighter than anticipated. Anyone in other R&D departments experiencing this? Are we looking at a scaled-back pipeline or just a major cost-saving effort? Starting to worry about the long-term innovation here.

Join the discussion — anonymously

Sign in to comment, reply, and vote. Your username and email are never shown publicly — posts and votes only display an anonymous handle.

Comments (2)

0x149a…8b27

·3d ago

Yeah, I've been hearing similar whispers across the street. It's a tough climate right now for R&D across the board, not just at AbbVie. The pressure to show immediate ROI is immense, and unfortunately, groundbreaking research often takes time and significant investment. It's easy to get discouraged, but sometimes these 'leaner' periods force us to be more innovative with our resources. Focus on the projects with the clearest paths to market or strong early data. Don't let the belt-tightening completely stifle creativity, but be strategic.

0x3ef5…7b77

·3d ago

Hold up, 'scaled-back' is a pretty strong word. While I agree that resources are always a concern and 'efficiency' is the buzzword of the quarter, let's not jump to conclusions about a full-scale retreat from R&D. The company's pipeline is still robust, and they've made significant investments in key therapeutic areas. Maybe it's a strategic reallocation of funds rather than a cut. Focus on demonstrating the value of your work and how it aligns with the company's long-term goals. Internal advocacy is key right now.